Welcome to our dedicated page for SCYNEXIS news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on SCYNEXIS stock.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a front-running pharmaceutical company dedicated to discovering, developing, and commercializing novel anti-infectives. Based in Jersey City, SCYNEXIS aims to address significant unmet therapeutic needs, particularly in the realm of fungal infections. Their primary product candidate, ibrexafungerp, is an innovative oral and intravenous drug targeting a wide range of serious and life-threatening invasive fungal infections.
SCYNEXIS is renowned for its groundbreaking antifungal platform known as “fungerps.” Ibrexafungerp, the first representative of this class, received FDA approval for treating vulvovaginal candidiasis (VVC) and for reducing the incidence of recurrent VVC. This compound is also in late-stage clinical trials targeting invasive fungal infections in hospitalized patients. SCYNEXIS is continuously advancing its pipeline with new antifungal candidates like SCY-247, which has shown promising preclinical results against multiple drug-resistant fungal pathogens.
In recent developments, SCYNEXIS voluntarily recalled two lots of BREXAFEMME® due to potential cross-contamination with a non-antibacterial beta-lactam substance. Although no adverse events have been reported, the company is taking proactive measures to address the issue and ensure consumer safety. Meanwhile, SCYNEXIS continues to make strides in research and development, with significant investments aimed at expanding their antifungal arsenal.
For more information about SCYNEXIS, Inc., including their latest news and updates, visit www.scynexis.com.
SCYNEXIS has announced that its partner, Hansoh Pharma, has filed an IND application for a Phase 3 study of ibrexafungerp in China, targeting vulvovaginal candidiasis. This follows an exclusive licensing agreement between the companies to develop and commercialize ibrexafungerp in the region. Ibrexafungerp is the first new antifungal drug approved by the FDA in over two decades, emphasizing its potential in combating drug-resistant infections. The collaboration aims to leverage Hansoh's capabilities to enhance treatment accessibility for patients in China.
SCYNEXIS, a biotechnology company focused on innovative treatments for drug-resistant infections, will participate in two upcoming virtual investor conferences in September 2021. The conferences include the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, featuring an on-demand presentation and one-on-one meetings, and the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, with a live presentation. More information and archived webcasts will be available on their website for 30 days post-event.
SCYNEXIS announced financial results for Q2 2021, showcasing a strong cash position of $112.4 million. The company reported a net income of $1.7 million, reversing a loss of $6.4 million from the previous year. BREXAFEMME, the first FDA-approved antifungal in over 20 years, launched in August 2021, with positive payer engagement. Clinical advancements include completing enrollment in the Phase 3 CANDLE study and ongoing Phase 1 trials for a liposomal IV formulation. The company expects to sustain operations into 2023 driven by anticipated sales of BREXAFEMME.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced the granting of stock options to five new employees, allowing them to purchase a total of 24,500 shares at an exercise price of $6.97 per share, the closing price on July 30, 2021. This grant serves as an incentive for accepting job offers and will vest over a four-year period. SCYNEXIS focuses on developing innovative antifungal treatments, including the recently FDA-approved BREXAFEMME (ibrexafungerp), targeting drug-resistant infections in both community and hospital settings.
SCYNEXIS, Inc. (NASDAQ: SCYX) presented data from two Phase 3 studies (VANISH-303 and VANISH-306) on oral ibrexafungerp for treating vulvovaginal candidiasis (VVC). The studies targeted patients with severe yeast infections and showed ibrexafungerp's efficacy and safety. Results indicated a Clinical Cure Rate of 56.9% for ibrexafungerp compared to 35.7% for placebo (p=0.001). The FDA approved BREXAFEMME® for the treatment of VVC, marking a significant milestone as the first new class of antifungal agent in over 20 years. Further studies are ongoing for recurrent VVC prevention.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced promising presentations for ibrexafungerp at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). The data highlight ibrexafungerp's effectiveness against challenging fungal infections, including drug-resistant Candida auris. In vitro studies showed broad activity of ibrexafungerp against 967 clinical isolates in Denmark. From the FURI study, 70% of patients with refractory fungal diseases demonstrated clinical improvement, while 80% of patients in the CARES study achieved a complete response for Candida auris infections.
SCYNEXIS, Inc. (NASDAQ: SCYX) has announced that CFO Eric Francois will present at Ladenburg Thalmann’s virtual Healthcare Conference on July 14, 2021, from 11:00 to 11:25 AM ET. This presentation will highlight the company’s innovative medicines aimed at combating drug-resistant infections, particularly their lead asset, ibrexafungerp. The company recently received FDA approval for BREXAFEMME (ibrexafungerp tablets) on June 1, 2021. The conference webcast will be accessible for three months on the SCYNEXIS website.
SCYNEXIS announced stock options grants for four new employees totaling 18,100 shares at an exercise price of $7.36, aligning with the closing price on June 30, 2021. The options, part of the 2015 Inducement Award Plan, vest over four years, promoting employee retention. This initiative aims to attract talent in the biotech sector, focusing on innovative antifungal treatments.
SCYNEXIS is advancing ibrexafungerp, a drug targeting drug-resistant fungal infections, with FDA approval for BREXAFEMME on June 1, 2021.
SCYNEXIS has announced an update for the commercial launch of BREXAFEMME (ibrexafungerp), the first FDA-approved antifungal in over 20 years, specifically for vaginal yeast infections. The launch call is set for June 29, 2021, at 12 PM ET, featuring key presentations from management and Dr. Michael L. Krychman. BREXAFEMME offers a new treatment option for vulvovaginal candidiasis (VVC) and is contraindicated during pregnancy. This innovative drug demonstrates a favorable safety profile and efficacy against various Candida strains. For more details, visit www.brexafemme.com.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced its participation in the BIO Digital International Convention from June 10-11 and June 14-18, 2021. Dr. Marco Taglietti, the company's CEO, will present the FDA-approved BREXAFEMME® (ibrexafungerp tablets) and discuss late-stage clinical trials for recurrent vaginal yeast infections and life-threatening fungal infections like Candida auris. Attendees can view the presentation ahead of one-on-one meetings starting June 14. SCYNEXIS focuses on developing innovative antifungal treatments aimed at tackling drug-resistant infections.
FAQ
What is the current stock price of SCYNEXIS (SCYX)?
What is the market cap of SCYNEXIS (SCYX)?
What does SCYNEXIS, Inc. specialize in?
What is ibrexafungerp?
What recent achievements has SCYNEXIS made?
Why did SCYNEXIS recall BREXAFEMME®?
What is SCY-247?
How does SCYNEXIS contribute to treating drug-resistant infections?
Who can I contact for more information about SCYNEXIS?
What are the financial highlights of SCYNEXIS?
Where is SCYNEXIS headquartered?
How can I report adverse reactions to SCYNEXIS products?
